Literature DB >> 23780781

Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI).

Changning Guo1, Diem Ngo, Shafiq Ahadi, William H Doub.   

Abstract

Abbreviated impactors have been developed recently to allow more rapid evaluation of inhalation products as alternates to the eight-stage Andersen Cascade Impactor (ACI) which has been widely used in the pharmaceutical industry for assessing aerodynamic particle size distribution. In this paper, a two-stage abbreviated impactor, Westech Fine Particle Dose Impactor (WFPD), was used to characterize the aerodynamic particle size of metered dose inhaler (MDI) products, and the results were compared with those obtained using the standard eight-stage ACI. Seven commercial MDI products, with different propellants (chlorofluorocarbon/hydrofluoroalkane) and formulation types (suspension/solution, dry/normal/wet), were tested in this study by both WFPD and ACI. Substantially equivalent measures of fine particle fraction were obtained for most of the tested MDI products, but larger coarse particle fraction and extra-fine particle fraction values were measured from WFPD relative to those measured using the ACI. Use of the WFPD also produced more wall loss than the ACI. Therefore, it is recommended that the system suitability be evaluated on a product-by-product basis to establish substantial equivalency before implementing an abbreviated impactor measurement methodology for routine use in inhaler product characterization.

Entities:  

Mesh:

Year:  2013        PMID: 23780781      PMCID: PMC3755172          DOI: 10.1208/s12249-013-9984-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  7 in total

Review 1.  Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations.

Authors:  Jolyon P Mitchell; Mark W Nagel
Journal:  J Aerosol Med       Date:  2003

2.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-05-18       Impact factor: 3.246

3.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 2--investigation of bias in extra-fine mass fraction with AIM-HRT impactor.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-07-10       Impact factor: 3.246

4.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

5.  The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-17       Impact factor: 3.246

6.  Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets.

Authors:  E Berg; P Lamb; A Ali; J Dennis; M Tservistas; J Mitchell
Journal:  Pharmeur Sci Notes       Date:  2008-02

7.  A sampler for respiratory health hazard assessment.

Authors:  A A Andersen
Journal:  Am Ind Hyg Assoc J       Date:  1966 Mar-Apr
  7 in total
  3 in total

1.  Promoted Antitumor Activity of Myricetin against Lung Carcinoma Via Nanoencapsulated Phospholipid Complex in Respirable Microparticles.

Authors:  Noha Nafee; Dina M Gaber; Ahmed O Elzoghby; Maged W Helmy; Osama Y Abdallah
Journal:  Pharm Res       Date:  2020-04-14       Impact factor: 4.200

Review 2.  Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review.

Authors:  Anna Lechanteur; Brigitte Evrard
Journal:  Pharmaceutics       Date:  2020-01-09       Impact factor: 6.321

Review 3.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.